Aspergillus Patents (Class 435/913)
  • Patent number: 8715716
    Abstract: This invention provides methods and compositions for producing reduced cholesterol animal foodstuffs and products by feeding livestock and other food-producing animals with feed supplemented with microbial cultures containing hypocholesterolemic compounds produced by microorganisms comprising said microbial cultures. The invention provides low cholesterol poultry, eggs, meat, whole milk, and dairy products.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: May 6, 2014
    Assignee: Jinis Biopharmaceuticals Co.
    Inventors: Seong-Tshool Hong, Hyeon-Jin Kim, Dae-Kwon Lee, Won-Young Yang
  • Patent number: 7785824
    Abstract: Process for the preparation of a hydrolysed casein product comprising tripeptides VPP, IPP and/or LPP, wherein a substrate comprising casein or casein fragments is subjected to enzyme treatment wherein the enzyme is derived from Aspergillus, wherein the enzyme concentration is 2-10 wt. % based on casein and that the enzyme has a high proteolytic activity.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: August 31, 2010
    Assignee: Conopco Inc.
    Inventors: Monique Cecilia van der Burg-Koorevaar, René´ Bernardus Draaisma, Johannes Schalk
  • Patent number: 7781409
    Abstract: A composition for external use, comprising 2-O-(?-D-glucopyranosyl)ascorbic acid represented by the formula (I): or a salt or ester thereof which is safe to the human body, and a koji mold or a processed koji. The composition for external use is excellent in skin permeability, containing an ascorbic acid derivative which is excellent in stability, utilized persistently in the living body, and strong in antioxidant activity, and has little skin irritation.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: August 24, 2010
    Assignee: Suntory Holdings Limited
    Inventors: Mitsuru Maeda, Masahiro Nakao, Harukazu Fukami
  • Patent number: 7063976
    Abstract: A process for preparing beta-fructofuranosidase enzyme and a process for producing fructooligosaccharides, in which the preparation of the enzyme is obtained by cultivating the fungus Aspergillus niger, either wild or mutated, in a preferably semi-solid culture medium, in order to produce an extracellular enzyme, which is submitted to transfructosylation for producing fructooligosaccharides comprising sugars which are formed by one unit of sacrose and by two, three and four units of fructose.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: June 20, 2006
    Assignee: Usina da Barra S/A—Acucar e Alcool
    Inventors: Yong Kun Park, Gláucia Maria Pastores
  • Patent number: 6858405
    Abstract: The present invention relates to a method which can prevent browning of hydrolyzed protein obtained by enzymatic hydrolysis of vegetable protein material. A vegetable protein material containing saccharides is mixed with the fungal culture and is subjected to enzymatic hydrolysis in a liquid reaction system. The reaction is conducted first at a temperature ranging from 15° C. to 39° C. with aeration and agitation, and then, after stopping the aeration, the reaction is conducted and completed at a temperature ranging from 40° C. to 60° C.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: February 22, 2005
    Assignee: Ajinomoto Co., Inc.
    Inventors: Michinobu Nakamura, Mitsuyoshi Seki, Miyoko Nawata, Hidetsugu Nakazawa, Hideki Okamura
  • Patent number: 6734004
    Abstract: A process for the production of a modified phytase with a desired property improved over the property of the corresponding unmodified phytase is disclosed, as well as modified phytases, polynucleotides encoding modified phytases, and animal feed including modified phytases.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: May 11, 2004
    Assignee: Roche Vitamins Inc.
    Inventors: Dirk Kostrewa, Luis Pasamontes, Andrea Tomschy, Adolphus van Loon, Kurt Vogel, Markus Wyss
  • Patent number: 6537798
    Abstract: A process for reforming oil fuel comprises the steps of contacting oil fuel with activated aspergillus fungi for a certain period and then mixing the resulting oil fuel with unreformed oil fuel. The reformed oil fuel may be treated with a magnetic catalyst after treatment by the activated aspergillus fungi.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: March 25, 2003
    Inventor: Hideaki Tanaka
  • Publication number: 20020155585
    Abstract: A process for reforming oil fuel comprises the steps of contacting oil fuel with activated aspergillus fungi for a certain period and then mixing the resulting oil fuel with unreformed oil fuel. The reformed oil fuel may be treated with a magnetic catalyst after treatment by the activated aspergillus fungi.
    Type: Application
    Filed: February 27, 2001
    Publication date: October 24, 2002
    Inventor: Hideaki Tanaka
  • Patent number: 6426202
    Abstract: A nystatin-resistant mutant microorganism belonging to Aspegillus genus is provided for preparing triol heptanoic acid, a precursor of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor. A mutant Aspergillus terreus CLS247-13, KCTC 0673 BP is prepared by treating Aspergillus terreus CLS216-7, KCTC 0359 BP with ultraviolet ray or chemical mutagens. The mutant provides high productivity (at least 11.5 g/L, 95/6% of the total product) of triol heptanoic acid, while reducing (less than 0.53 g/L, 4.4% of total product) productivity of triol heptanoic acid analogues. Since the nystatin-resistant mutant strain CLS347-13 has a capability of producing triol heptanioc acid with a high yield in a short period of culture time compared with known triol heptanoic acid producing strains, it can be widely used in industrial applications.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: July 30, 2002
    Assignee: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Chung-II Hong, Kyung-Hwan Kim, Byoung-Taek Choi, Jang Woo Park, Nak Kyu Sung, Byoung Kook Kim
  • Patent number: 6387652
    Abstract: Fungi and bacteria can be detected and rapidly quantified by using the nucleotide sequences taught here that are specific to the particular species or group of species of fungi or bacteria. Use of the sequences can be made with fluorescent labeled probes, such as in the TaqMan™ system which produces real time detection of polymerase chain reaction (PCR) products. Other methods of detection and quantification based on these sequences include hybridization, conventional PCR or other molecular techniques.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: May 14, 2002
    Assignee: U.S. Environmental Protection Agency
    Inventors: Richard Haugland, Stephen Vesper
  • Patent number: 6361979
    Abstract: The present invention relates to processes for the microbial oxidation of 2-methylquinoxaline to 2-quinoxalinecarboxylic acid which comprise contacting 2-methylquinoxaline with a microorganism, or a suitable mutant thereof, and incubating the resulting mixture under conditions sufficient to yield an amount of said 2-quinoxalinecarboxylic acid. The present processes optionally further comprise the isolation and purification of 2-quinoxalinecarboxylic acid.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: March 26, 2002
    Assignee: Pfizer Inc.
    Inventors: Michael P. Burns, James J. Cawley, John W. Wong
  • Patent number: 6291231
    Abstract: The present invention is a microorganism which is Aspergillus candidus RF-5762 (FERM BP-5882), wherein said microorganism is capable of producing a compound of the following formula (I): wherein R1 is hydrogen or hydroxy and R2 is hydroxy or methoxy.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: September 18, 2001
    Assignee: Shionogi & Co., Ltd.
    Inventors: Toshiyuki Kamigauchi, Ryuji Suzuki
  • Patent number: 6153596
    Abstract: The present invention relates to improved methods for introducing nucleic acid into cells by first complexing the nucleic acid with a selected polycationic oligomer which neutralizes the negative charge of the nucleic acid, and then contacting the cell with the complex facilitating uptake of the nucleic acid into the cells as a complex with the oligomer. The methods are preferably applied to introduction of nucleic acid into eukaryotic cells, and more preferably into human cells. The invention also relates to methods of introducing antisense and triplex-forming oligonucleotides into prostate cancer cells to inhibit expression of proteins associated with (or that promote) malignancy and to inhibit cell growth or proliferation. More particularly, the invention relates to a method for inhibiting the expression of the HER-2/NEU protein in prostate cancer cells and to a method for inhibiting prostate cancer cell growth or proliferation.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: November 28, 2000
    Assignee: Emory University
    Inventors: Dennis C. Liotta, John A. Petros, Shiow-Jyi Wey, Joan F. Karr, Jan Pohl
  • Patent number: 6150141
    Abstract: The present invention makes available methods and reagents for novel manipulation of nucleic acids. As described herein, the present invention makes use of the ability of intronic sequences, such as derived from group I, group II, or nuclear pre-mRNA introns, to mediate specific cleavage and ligation of discontinuous nucleic acid molecules. For example, novel genes and gene products can be generated by admixing nucleic acid constructs which comprise exon nucleic acid sequences flanked by intron sequences that can direct trans-splicing of the exon sequences to each other. The flanking intronic sequences can, by intermolecular complementation, form a reactive complex which promotes the transesterification reactions necessary to cause the ligation of discontinuous nucleic acid sequences to one another, and thereby generate a recombinant gene comprising the ligated exons.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: November 21, 2000
    Assignee: Trustees of Boston University
    Inventor: Kevin A. Jarrell
  • Patent number: 6140112
    Abstract: The present invention pertains to the use of compounds affecting the activity of transcription factors for the preparation of a pharmaceutical composition for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: April 25, 1996
    Date of Patent: October 31, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Jacques Mallet, Frederic Revah, Jean-Jacques Robert
  • Patent number: 6140094
    Abstract: This invention relates to a protein having phospholipase activity, which is characterised in that it has the mature sequence of Aspergillus lysophospholipase or a sequence derived therefrom and that it may be cleaved at at least one site, wherein, in the event of cleavage, the restriction fragments are optionally either linked by means of at least one bond cleavable under reducing conditions or at least one of the unlinked restriction fragments has phospholipase activity, and to a process for the production of this protein by fermenting a suitably transformed lysophospholipase-producing host organism in a suitable culture medium and isolating the protein having phospholipase activity from the cell-free culture filtrate, wherein fermentation is performed in the acidic to slightly alkaline range.
    Type: Grant
    Filed: September 8, 1998
    Date of Patent: October 31, 2000
    Assignee: Rohm GmbH
    Inventors: Fridolin Loffler, Gerald Jungschaffer, Quoc Nguyen Khanh, Erwin Schuster, Bruno Sprossler, Sabine Wolf
  • Patent number: 6139902
    Abstract: This invention relates to an inexpensive phytase with a low Km value for phytic acid, DNA coding for the phytase, recombinant DNA having the DNA introduced thereinto, a transformant carrying the recombinant DNA, a process for preparing a phytase by use of the transformant, and an animal feed comprising the phytase.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: October 31, 2000
    Assignees: Kyowa Hakko Kogyo Co., Ltd., Shin Nihon Chemical Co., Ltd.
    Inventors: Hidemasa Kondo, Hideharu Anazawa, Syunichi Kaneko, Tadashi Nagashima, Tatsuya Tange
  • Patent number: 6121025
    Abstract: The present invention relates to a process for producing optically active 3-quinuclidinol or derivatives, wherein a racemic 3-quinuclidinol ester represented by the general formula (I): ##STR1## wherein R represents a straight-chain or branched alkyl group, and (H.sup.+) represents that said ester may be in the form of a salt formed with a mineral acid or an organic acid, is reacted with a microorganism belonging to the genus Aspergillus, Rhizopus, Candida or Pseudomonas having the ability to asymmetrically hydrolyze said ester linkage, a culture of said microorganism, a treated material from said microorganism, an enzyme produced by said microorganism, or an enzyme derived from swine or cattle.According to the present invention, there is provided a process for easily producing optically active 3-quinuclidinol derivatives which are important synthetic intermediates for pharmaceutical preparations etc.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: September 19, 2000
    Assignee: Mitsubishi Rayon Co., Ltd.
    Inventors: Eiji Sato, Kanehiko Enomoto
  • Patent number: 6117657
    Abstract: Enzymatic nucleic acid molecule containing one or more non-nucleotide mimetics, and having activity to cleave an RNA or DNA molecule.
    Type: Grant
    Filed: October 29, 1998
    Date of Patent: September 12, 2000
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Nassim Usman, Francine Wincott, Jasenka Matulic-Adamic, Leonid Beigelman, Alex Karpeisky
  • Patent number: 6110680
    Abstract: An improved method for the simultaneous sequence-specific identification of mRNAs in a mRNA population allows the visualization of nearly every mRNA expressed by a tissue as a distinct band on a gel whose intensity corresponds roughly to the concentration of the mRNA. In general, the method comprises the formation of cDNA using anchor primers to fix a 3'-endpoint, producing cloned inserts from the cDNA in a vector containing a bacteriophage-specific promoter for subsequent RNA synthesis, generating linearized fragments of the cloned inserts, preparing cRNA, transcribing cDNA from the cRNA using a set of primers, and performing PCR using a 3'-primer whose sequence is derived from the vector and a set of 5'-primers that is derived from the primers used for transcription of cDNA from cRNA. The method can identify changes in expression of mRNA associated with the administration of drugs or with physiological or pathological conditions.
    Type: Grant
    Filed: June 30, 1998
    Date of Patent: August 29, 2000
    Assignee: The Scripps Research Institute
    Inventors: J. Gregor Sutcliffe, Mark G. Erlander, Karl W. Hasel
  • Patent number: 6110520
    Abstract: A process for producing high yields of .gamma.-hexalactone and 2-pentanone from the corresponding hexanoic acid starting material is carried out with high amounts of oxygen and sugar in the presence of a mold microorganism. Fragrance compositions and foodstuff compositions are augmented and enhanced by the presence of the product compounds.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: August 29, 2000
    Assignee: International Flavors & Fragrances Inc.
    Inventors: Fenjin He, Mohamad I. Farbood, Laura E. Kizer
  • Patent number: 6107094
    Abstract: Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: August 22, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Patent number: 6096880
    Abstract: The present invention provides methods for synthesis, and therapeutic use of DNA and RNA oligonucleotides and analogs. RNA oligonucleotides arc synthesized using a small, circular DNA template which lacks an RNA polymerase promoter sequence. The RNA synthesis is performed by combining a circular single-stranded oligonucleotide template with an effective RNA polymerase and at least two types of ribonucleotide triphosphate to form an RNA oligonucleotide multimer comprising multiple copies of the desired RNA oligonucleotide sequence. Preferably, the RNA oligonucleotide multimer is cleaved to produce RNA oligonucleotides having well-defined ends. Preferred RNA oligonucleotide multimers contain ribozymes capable of both cis (autolytic) and trans cleavage.
    Type: Grant
    Filed: February 26, 1997
    Date of Patent: August 1, 2000
    Assignee: University of Rochester
    Inventor: Eric T. Kool
  • Patent number: 6093542
    Abstract: An isothermal transcription based amplification assay for MDC RNA uses primer combinations for sequences within the MDC gene. A quantitative control uses a mutant RNA for comparison.
    Type: Grant
    Filed: January 9, 1998
    Date of Patent: July 25, 2000
    Assignee: Akzo Nobel N.V.
    Inventors: Joseph Romano, Ranajit Pal, Roxanne Shurtliff
  • Patent number: 6087540
    Abstract: The present invention provides a compound of the formula (I): ##STR1## wherein R.sup.1 is hydrogen or hydroxy and R.sup.2 is hydroxy or methoxy, pharmaceutically acceptable salts or hydrates thereof, a process for producing the same, a pharmaceutical composition which comprises the same and a microorganism which belongs to Aspergillus candidus and produces the compound.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: July 11, 2000
    Assignee: Shionogi & Co., Ltd.
    Inventors: Toshiyuki Kamigauchi, Ryuji Suzuki
  • Patent number: 6087123
    Abstract: The invention relates to bioactive ribonucleo polypeptides (RNP) containing copper, zinc or calcium. These are non-mitogenic morphogens for blood vessels of a defined primary structure for intercellular communication with genetic information. Zn/Ca/Cu-RNP can enzymatically hydrolyse nucleinic acids in a regulated manner (regulated nuclease activity) and be modulated and regulated via Zn/Ca/Cu-metal ion contents as "molecular switches" in mutual bioactivity. The compounds selectively stimulate the directional growth of the morphogenesis of blood vessels in vivo and in vitro and lead to neovascularisation of tissues. The invention further relates to a method of producing and obtaining the RNP as well as its utilisation, and medicines.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: July 11, 2000
    Assignee: Fraunhofer-Gesellschaft zur Foerderung der Angewandten Forschung e.V.
    Inventors: Josef Wissler, Enno Logemann, Stefan Kiesewetter, Ludwig Heilmeyer
  • Patent number: 6077668
    Abstract: The present invention provides detectably labeled RNA and DNA oligonucleotide multimers useful as diagnostic probes in medical, biological and chemical applications. A method for synthesizing DNA and RNA oligonucleotides, oligonucleotide multimers, and analogs, preferably those that are detectably labeled, is also provided. Oligonucleotide synthesis is performed by combining a circular single-stranded oligonucleotide template with an effective polymerase and at least two types of nucleotide triphosphate, without the addition of auxiliary proteins, to yield an oligonucleotide multimer comprising multiple copies of a repeated oligonucleotide sequence.
    Type: Grant
    Filed: August 13, 1997
    Date of Patent: June 20, 2000
    Assignee: University of Rochester
    Inventor: Eric T. Kool
  • Patent number: 6063628
    Abstract: The present invention is directed to the identification and use of ribonucleoside analogs to induce the mutation of an RNA virus, including HIV and HCV, or a virus which otherwise replicates through an RNA intermediate. The increase in the mutation rate of the virus results in reduced viability of progeny generations of the virus, thereby inhibiting viral replication. In addition to these methods and related compositions, the invention provides methods and combinatorial chemistry libraries for screening ribonucleoside analogs for mutagenic potential.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: May 16, 2000
    Assignee: University of Washington
    Inventors: Lawrence A. Loeb, James I. Mullins
  • Patent number: 6060023
    Abstract: A molecular sensing apparatus comprises a first electrode (10), a second electrode (12), a first molecule (20), a second molecule (22), and a third molecule (34). The first molecule (20) has a first chain of nucleic bases (30) and a first group (24). The first group (24) is bound to the first electrode (10). The second molecule (22) has a second chain of nucleic bases (32) and a second group (26). The second group (26) is bound to the second electrode (12). The third molecule (34) is bound to the first molecule (20) and the second molecule (22). A method which uses the molecular sensing apparatus is disclosed.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: May 9, 2000
    Assignee: Motorola, Inc.
    Inventor: George N. Maracas
  • Patent number: 6037126
    Abstract: The present invention is directed to methods, compositions, kits and apparatus to identify and detect the presence or absence of target analytes. The embodiments of the present invention have utility in identification of protein component of human telomerase and measurement of its levels in specimens and samples, as well as the design of test kits and apparatus for implementing such methods.
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: March 14, 2000
    Assignee: InVitro Diagnostics, Inc.
    Inventor: Abraham Grossman
  • Patent number: 6030784
    Abstract: An improved method for the simultaneous sequence-specific identification of mRNAs in a mRNA population allows the visualization of nearly every mRNA expressed by a tissue as a distinct band on a gel whose intensity corresponds roughly to the concentration of the mRNA. In general, the method comprises the formation of cDNA using anchor primers to fix a 3'-endpoint, producing cloned inserts from the cDNA in a vector containing a bacteriophage-specific promoter for subsequent RNA synthesis, generating linearized fragments of the cloned inserts, preparing cRNA, transcribing cDNA from the cRNA using a set of primers, and performing PCR using a 3'-primer whose sequence is derived from the vector and a set of 5'-primers that is derived from the primers used for transcription of cDNA from cRNA. The method can identify changes in expression of mRNA associated with the administration of drugs or with physiological or pathological conditions.
    Type: Grant
    Filed: March 5, 1998
    Date of Patent: February 29, 2000
    Assignee: The Scripps Research Institute
    Inventors: J. Gregor Sutcliffe, Mark G. Erlander
  • Patent number: 6027724
    Abstract: Non-toxigenic strains of Aspergillus such as from the species Aspirgillus oryzae and Aspergillus sojae are useful fungal biocontrol agents for preventing toxin contamination in agricultural commodities, especially those for human consumption such as peanuts and corn. These strains do not produce aflatoxin, any bis-furan ring-containing intermediates of the aflatoxin biosynthetic pathway and cyclopiazonic acid. They are also useful for controlling toxin damage to crops such as cotton. The strains include Aspergillus strains NRRL 21368, NRRL 21369, NRRL 21882, NRRL 30038, NRRL 30039 and mixtures thereof.
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: February 22, 2000
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Joe W. Dorner, Bruce W. Horn, Richard J. Cole
  • Patent number: 6022714
    Abstract: Compositions and methods for selectively linking a polynucleotide through its 5' or 3' end to one or more preselected materials such as insoluble matrices, solid supports, proteins, small molecular or labels are disclosed. Use of these compositions and methods in the production of diagnostic and affinity reagents are also disclosed.
    Type: Grant
    Filed: December 19, 1995
    Date of Patent: February 8, 2000
    Assignee: Genetics Institute
    Inventors: Eugene L. Brown, Joseph P. Dougherty, Mary Collins
  • Patent number: 6020184
    Abstract: A biodegradation method for polyorganosiloxanes (POS), particularly polydimethylsiloxanes (PDMS), includes contacting the POS with one or more microscopic fungi, preferably in the presence of at least one co-substrate, said fungus being selected from the family of Corticiacea, preferably of the genus Phanaerochaete or Aspergillus, more preferably Aspergillus sydowii BJS94, Phanerochaete sordida and Phanerochaete chrysosporium. A screening method comprises contacting a microscopic fungus with POS, preferably with PDMS, in the presence of a co-substrate, and evaluating the capacity of the fungus to degrade the POS. The fungi disclosed in the invention can be used in the biodegradation method. An isolate of Aspergillus sydowii BJS94 is also disclosed.
    Type: Grant
    Filed: December 30, 1997
    Date of Patent: February 1, 2000
    Assignee: Rhone-Poulenc Chimie
    Inventors: Frederic Baud-Grasset, Jean-Claude Palla
  • Patent number: 6017696
    Abstract: A self-addressable, self-assembling microelectronic device is designed and fabricated to actively carry out and control multi-step and multiplex molecular biological reactions in microscopic formats. These reactions include nucleic acid hybridizations, antibody/antigen reactions, diagnostics, and biopolymer synthesis. The device can be fabricated using both microlithographic and micro-machining techniques. The device can electronically control the transport and attachment of specific binding entities to specific micro-locations. The specific binding entities include molecular biological molecules such as nucleic acids and polypeptides. The device can subsequently control the transport and reaction of analytes or reactants at the addressed specific micro-locations. The device is able to concentrate analytes and reactants, remove non-specifically bound molecules, provide stringency control for DNA hybridization reactions, and improve the detection of analytes. The device can be electronically replicated.
    Type: Grant
    Filed: July 7, 1994
    Date of Patent: January 25, 2000
    Assignee: Nanogen, Inc.
    Inventor: Michael J. Heller
  • Patent number: 6015712
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of FADD. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding FADD. Methods of using these compounds for modulation of FADD expression and for treatment of diseases associated with expression of FADD are provided.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: January 18, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Brenda F. Baker, Hong Zhang, Lex M. Cowsert
  • Patent number: 6013487
    Abstract: The molecules and methods of the present invention provide a means for in vivo production of a therapeutic molecule in a selected subset of cells. The pre-therapeutic molecules of the invention are substrates for a trans-splicing reaction between the pre-therapeutic molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides an active therapeutic RNA which is functional as RNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or a toxin which causes killing of the specific cells.
    Type: Grant
    Filed: December 13, 1996
    Date of Patent: January 11, 2000
    Inventor: Lloyd G. Mitchell
  • Patent number: 6013437
    Abstract: A method for identifying translationally regulated genes includes selectively stimulating translation of an unknown target mRNA with a stress inducing element wherein the target mRNA is part of a larger sample of mRNA. The mRNA sample is divided into pools of translated and untranslated mRNA which are differentially analyzed to identify genes that are translationally regulated by the stress inducing element. A method for identifying gene sequences coding for internal ribosome entry sites includes inhibiting 5' cap-dependant mRNA translation in a cell, collecting a pool of mRNA from the cells, and differentially analyzing the pool of mRNA to identify genes with sequences coding for internal ribosome entry sites.
    Type: Grant
    Filed: November 12, 1996
    Date of Patent: January 11, 2000
    Assignee: QBI Enterprises, Ltd.
    Inventors: Sylvie Luria, Paz Einat, Nicholas Harris, Rami Skaliter, Zehava Grosman
  • Patent number: 6010906
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Jun N-terminal Kinase Kinase-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Jun N-terminal Kinase Kinase-1. Methods of using these compounds for modulation of Jun N-terminal Kinase Kinase-1 expression and for treatment of diseases associated with expression of Jun N-terminal Kinase Kinase-1 are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: January 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Lex M. Cowsert
  • Patent number: 6001640
    Abstract: A degumming step in the production of edible oils is disclosed. Vegetable oils from which hydratable phosphatides have preferably been eliminated by a previous aqueous degumming process, are freed from non-hydratable phosphatides by an enzymatic treatment, so that they may be physically refined. The main characteristic of the invention is the use of phospholipase from an Aspergillus strain. The process is gentle, economical and environment-friendly.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: December 14, 1999
    Assignees: Roehm GmbH, Metallgesellschaft AG
    Inventors: Fridolin Loeffler, Hermann Plainer, Bruno Sproessler, Hans Ottofrickenstein
  • Patent number: 5989870
    Abstract: A method is described for the identification and cloning of promoters that express under a defined environmental condition, such as growth in glucose medium. Using this method, five Trichodermal promoters capable of the high expression of operably linked coding sequences are identified, one of which is the promoter for T. reesei tef1. Also provided are altered cbh1 promoters, altered so that glucose no longer represses expression from such promoter. The invention further provides vectors and hosts that utilize such promoters, and unique fungal enzyme compositions from such hosts.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: November 23, 1999
    Assignee: Rohm Enzyme Finland Oy
    Inventors: Tiina Hannele Nakari, Maija-Leena Onnela, Marja Hannele Ilmen, Merja Elisa Penttila
  • Patent number: 5990302
    Abstract: A method for isolating a ribonucleic acid, which comprises dissolution of a sample containing the ribonucleic acid, such as cells, in an acidic solution containing a lithium salt and a chaotropic agent, bringing the ribonucleic acid into contact with a nucleic acid-binding carrier such as silica particles, thereby to allow selective adsorption of the ribonucleic acid alone onto said carrier, and eluting the ribonucleic acid from the nucleic acid-bound carrier; a reagent therefor; and a method for producing a cDNA from the ribonucleic acid isolated by this method. According to the present invention, a high purity ribonucleic acid can be isolated quickly and safely from a sample containing the ribonucleic acid.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: November 23, 1999
    Assignee: Toyo Boseki Kabushiki Kaisha
    Inventors: Toshihiro Kuroita, Hideki Kamimura, Bunsei Kawakami, Yoshihisa Kawamura
  • Patent number: 5985620
    Abstract: This invention describes compounds active against TNF-.alpha. mRNA. It further describes RNA molecules capable of conferring stability to RNA in vivo through an endogenous ribozyme binding protein(s). Possible mRNA molecules to be stabilized include ribozymes, antisense molecules and mRNA encoding polypeptides useful for protein production. The ribozymes and antisense molecules described herein are useful in mammals and plants, particularly suited for viral diseases. Methods of production and methods of use are also described.
    Type: Grant
    Filed: June 22, 1995
    Date of Patent: November 16, 1999
    Assignee: Gene Shears Pty. Limited
    Inventor: Mouldy Sioud
  • Patent number: 5981183
    Abstract: In a method for amplifying the specific nucleic acid sequence, a highly specific amplification which has low possibility of non-specific hybridization can be carried out. Highly stable reagents, the activities of which do not decrease in case of supply and storage, are also provided. Thermostable enzymes are used as RNA dependent DNA polymerase, DNA dependent DNA polymerase, DNA dependent RNA polymerase and ribonuclease H, which are required for the amplification system based on replicated RNA. Especially, it is preferable that a thermostable enzyme derived from Thermus thermophilus which has RNA dependent DNA polymerase activity, DNA dependent DNA polymerase activity and ribonuclease H activity, and thermostable DNA dependent RNA polymerase are used together. By this method, inactivation of enzymes are prevented by using thermostable enzymes, and the amplification can be carried out without sequential addition of enzymes.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: November 9, 1999
    Assignee: Toyo Boseki Kabushiki Kaisha
    Inventors: Yutaka Takarada, Hiroaki Inoue, Shuji Shibata, Yoshihisa Kawamura
  • Patent number: 5976855
    Abstract: The present invention relates to a method of preparing a variant of a parent lipolytic enzyme, comprising (a) subjecting a DNA sequence encoding the parent lipolytic enzyme to random mutagenesis, (b) expressing the mutated DNA sequence obtained in step (a) in a host cell, and (c) screening for host cells expressing a mutated lipolytic enzyme which has a decreased dependance to calcium and/or an improved tolerance towards a detergent or a detergent component as compared to the parent lipolytic enzyme.
    Type: Grant
    Filed: August 22, 1996
    Date of Patent: November 2, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Allan Svendsen, Ib Groth Clausen, Jens Sigurd Okkels, Marianne Thellersen
  • Patent number: 5973137
    Abstract: The present invention describes an RNA isolation process which utilizes low pH reagents. In addition, the reagents are less hazardous and are more stable than those used in prior art methods. This rapid method may be used to obtain purified RNA from a variety of biological sources including human whole blood, plant and animal tissues, cultured cells, body fluids, yeast, and bacteria.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: October 26, 1999
    Assignee: Gentra Systems, Inc.
    Inventor: Ellen M. Heath
  • Patent number: 5968506
    Abstract: This invention provides purified human telomerase and methods of purifying it. The methods involve the use of several sequential steps, including the use of a first matrix that binds molecules bearing negative charges, a matrix that binds molecules bearing positive charges, a second matrix that binds molecules bearing negative charges, an affinity purification step and a matrix that separates molecules according to their size.
    Type: Grant
    Filed: April 4, 1997
    Date of Patent: October 19, 1999
    Assignee: Geron Corporation
    Inventors: Scott L. Weinrich, Edward M. Atkinson, III, Serge P. Lichtsteiner, Alain P. Vasserot, Ronald A. Pruzan, James T. Kealey
  • Patent number: 5968785
    Abstract: We have developed efficient methods of creating artificial transposons and inserting these transposons into plasmid targets in vitro, primarily for the purpose of mapping and sequencing DNA. A plasmid has been engineered to convert virtually any DNA sequence, or combination of sequences, into an artificial transposon; hence, custom transposons containing any desired feature can be easily designed and constructed. Such transposons are then efficiently inserted into plasmid targets, in vitro, using the integrase activity present in yeast Ty1 virus-like particles. Primers complementary to the transposon termini can be used to sequence DNA flanking any transposon insertion.
    Type: Grant
    Filed: February 6, 1997
    Date of Patent: October 19, 1999
    Assignee: The Johns Hopkins University
    Inventors: Scott E. Devine, Jef D. Boeke, Lelita T. Braiterman
  • Patent number: 5955589
    Abstract: Oligonucleotides and other macromolecules are provided which have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and subsequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 21, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Phillip Dan Cook, Brett P. Monia
  • Patent number: 5945525
    Abstract: A nucleic acid-bondable magnetic carrier of the present invention is a magnetic silica particle comprising a superparamagnetic metal oxide, wherein the magnetic silica particle has a specific surface of about 100 to about 800 m.sup.2 /g.
    Type: Grant
    Filed: July 8, 1996
    Date of Patent: August 31, 1999
    Assignee: Toyo Boseki Kabushiki Kaisha
    Inventors: Hiroaki Uematsu, Katsuya Daimon, Satoko Yoshiga